natgillin/translations-raw huggingface dataset:
Two further studies in a total of 1,012 patients compared Insulin lispro Sanofi with Humalog and found them to be similarly effective at reducing blood levels of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose levels are controlled over time.
Dve nadaljnji študiji pri skupaj 1 012 bolnikih sta primerjali zdravilo Insulin lispro Sanofi z zdravilom Humalog in ugotovili, da sta podobno učinkoviti pri zniževanju ravni snovi v krvi, imenovane glikirani hemoglobin (HbA1c).
Insulin lispro Sanofi is a ‘biosimilar medicine'.
Zdravilo Insulin lispro Sanofi je „podobno biološko zdravilo“.
Insulin lispro Sanofi is given as an injection under the skin in the upper arm, thigh, buttock or belly.
Zdravilo Insulin lispro Sanofi se injicira v podkožje, in sicer v nadlaket, stegno, zadnjico ali trebuh.
What is Insulin lispro Sanofi and what is it used for?
Kaj je zdravilo Insulin lispro Sanofi in za kaj se uporablja?
Other information about Insulin lispro Sanofi
Druge informacije o zdravilu Insulin lispro Sanofi
What are the risks associated with Insulin lispro Sanofi?
Kakšna tveganja so povezana z zdravilom Insulin lispro Sanofi?
It contains the active substance insulin lispro.
Vsebuje zdravilno učinkovino insulin lispro.
What benefits of Insulin lispro Sanofi have been shown in studies?
Kakšne koristi je zdravilo Insulin lispro Sanofi izkazalo v študijah?
Why is Insulin lispro Sanofi approved?
Zakaj je bilo zdravilo Insulin lispro Sanofi odobreno?
How does Insulin lispro Sanofi work?
Kako zdravilo Insulin lispro Sanofi deluje?
How is Insulin lispro Sanofi used?
Kako se zdravilo Insulin lispro Sanofi uporablja?
The European Commission issued a decision on 28 September 2012.
Evropska komisija je odločbo izdala dne 28. septembra 2012.
France, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom).
Luksemburg, Malta, Norveška, Poljska, Portugalska, Romunija, Slovaška, Slovenija, Španija, Švedska in Združeno kraljestvo).
Why was Yvidually reviewed?
Zakaj je bilo zdravilo Yvidually pregledano?
However, the Member States were not able to reach an agreement and the Netherlands referred the matter to the CHMP for arbitration on 23 February 2012.
Vendar pa države članice niso uspele doseči soglasja, zato je Nizozemska 23. februarja 2012 zadevo napotila na CHMP v arbitražo.
This is a procedure where one Member State (the ‘reference Member State', in this instance the Netherlands) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, Finland,
To je postopek, v katerem ena od držav članic („referenčna država članica“, v tem primeru Nizozemska) oceni zdravilo z namenom odobritve dovoljenja za promet z zdravilom, ki bo veljavno v tej državi in drugih državah članicah („zadevne države članice“, v tem primeru Avstrija, Belgija, Bolgarija, Ciper, Češka republika, Danska, Estonija, Nemčija, Grčija, Finska, Francija, Madžarska, Islandija, Irska, Italija, Latvija, Litva,
France was also concerned that the tablet dispenser had not been used in the main clinical studies.
Francija je imela pomisleke tudi glede tega, da delilnik tablet ni bil uporabljen v glavnih kliničnih študijah.
Yvidually is a combined contraceptive pill.
Zdravilo Yvidually je kombinirana kontracepcijska tableta.
On 19 April 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Yvidually and associated names.
Evropska agencija za zdravila je 19. aprila 2012 zaključila postopek arbitraže, do katerega je prišlo po nesoglasju med državami članicami Evropske unije (EU) glede odobritve zdravila Yvidually in povezanih imen.
Yvidually is an ‘extended use' oral contraceptive, which means that it can be taken daily for up to 120 days.
Zdravilo Yvidually je peroralno kontracepcijsko sredstvo s „podaljšano uporabo“, kar pomeni, da se lahko jemlje vsak dan do 120 dni skupaj.
Based on evaluation of the available data and the scientific discussion within the Committee, the CHMP concluded that the contraceptive effectiveness during an extended use had been demonstrated.
CHMP je na podlagi ocene razpoložljivih podatkov in znanstvene razprave v Odboru zaključil, da je bila učinkovitost kontracepcijskega sredstva med podaljšano uporabo dokazana.
It contains two active substances, ethinylestradiol and drospirenone, which are derived from natural hormones produced in the ovaries: ethinylestradiol is derived from oestrogen and drospirenone is derived from progesterone.
Vsebuje dve zdravilni učinkovini, etinilestradiol in drospirenon, pridobljeni iz naravnih hormonov, ki se tvorita v jajčnikih: etinilestradiol se pridobiva iz estrogena, drospirenon pa iz progesterona.
While different bleeding patterns had been reported during the days of pill intake, these bleeding episodes seemed to be well tolerated.
Čeprav so ženske poročale o različnih vzorcih krvavitev v dneh jemanja tablet, se zdi, da so te krvavitve dobro prenašale.
What is Yvidually?
Kaj je zdravilo Yvidually?
The grounds for the referral were concerns by France about the effectiveness of the proposed extended use of the medicine and the irregular bleeding episodes that might occur during the days of intake of the pill.
Razlog za napotitev so bili pomisleki Francije o učinkovitosti predlagane podaljšane uporabe zdravila in neredne krvavitve, do katerih lahko pride med obdobjem jemanja tablet.
This medicine will be marketed also as Flexyess.
To zdravilo se bo tržilo tudi pod imenom Flexyess.
Yvidually works by changing the body's hormonal balance to prevent ovulation, by altering the mucus in the cervix (neck of the womb) and by thinning the endometrium (the lining of the womb).
Zdravilo Yvidually deluje tako, da spremeni hormonsko ravnovesje telesa in s tem prepreči ovulacijo, povzroči spremembo sluzi v cerviksu (materničnem vratu) ter tanjša endometrij (maternično sluznico).
The CHMP also noted that the concerns over the tablet dispenser had been adequately addressed, as an additional study provided by the company showed that women find the dispenser easy to use and that there were no problems with posology compliance.
CHMP je ugotovil tudi, da so bili pomisleki glede delilnika tablet ustrezno obravnavani, saj je dodatna študija, ki jo je izvedla družba, pokazala, da so ženske delilnik ocenile kot enostaven za uporabo in da ni bilo nobenih težav s pravilnim odmerjanjem.
The option of a tablet-free interval at any time during day 25 to 120 of the treatment cycle is also allowed.
Prav tako je možno za določeno obdobje prekiniti jemanje tablet, in sicer kadar koli med 25. in 120. dnevom ciklusa jemanja.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Yvidually outweigh its risks, and the marketing authorisation can be granted in all EU Member States as well as Iceland and Norway.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da koristi zdravila Yvidually odtehtajo njegova tveganja in da se lahko odobri dovoljenje za promet v vseh državah članicah EU ter v Islandiji in na Norveškem.
Yvidually will be available as tablets in an automated tablet dispenser device with a reminder function for when the next pill has to be taken.
Zdravilo Yvidually bo na voljo v obliki tablet, shranjenih v avtomatskem delilniku tablet, ki uporabnika opomni, da je čas za naslednji odmerek.
The CHMP therefore concluded that the benefits of Yvidually outweigh its risks, and therefore the marketing authorisation for Yvidually should be granted in all concerned Member States.
CHMP je tako zaključil, da so koristi zdravila Yvidually večje od z njim povezanih tveganj, in priporočil, da se dovoljenje za promet z zdravilom Yvidually odobri v vseh zadevnih državah članicah.
Bayer B.V. submitted Yvidually to the Netherlands medicines regulatory agency for a decentralised procedure.
je nizozemski regulatorni agenciji za zdravila predložila vlogo za pridobitev dovoljenja za promet z zdravilom Yvidually po decentraliziranem postopku.
The European Commission granted a marketing authorisation valid throughout the European Union for Glidipion on 15 March 2012.
Evropska komisija je dovoljenje za promet z zdravilom Glidipion, veljavno po vsej Evropski uniji, odobrila dne 15. marca 2012.
The full EPAR for Glidipion can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Glidipion je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This means that Glidipion is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
Treatment with Glidipion should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Zdravljenje z zdravilom Glidipion je treba ponovno oceniti po treh do šest mesecih in ga pri bolnikih, ki od njega nimajo zadostne koristi, ukiniti.
For more information about treatment with Glidipion, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Glidipion preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This is a summary of the European public assessment report (EPAR) for Glidipion.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Glidipion.
The active substance in Glidipion, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Zdravilna učinkovina zdravila Glidipion, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glidipion.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Glidipion, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about Glidipion
Druge informacije o zdravilu Glidipion
Because Glidipion is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Glidipion generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Glidipion is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Zdravilo Glidipion se uporablja za zdravljenje sladkorne bolezni tipa 2 pri odraslih (starejših od 18 let), zlasti tistih s prekomerno telesno maso.
The Committee recommended that Glidipion be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Glidipion odobri dovoljenje za promet.
This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed.
Priporočeni začetni odmerek zdravila Glidipion je 15 ali 30 mg enkrat na dan. Odmerek bo po enem ali dveh tednih morda treba povečati do 45 mg enkrat na dan, če je potreben boljši nadzor glukoze (sladkorja) v krvi.
The CHMP concluded that, in accordance with EU requirements, Glidipion has been shown to have comparable quality and to be bioequivalent to Actos.
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Glidipion primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
Glidipion is a ‘generic medicine'.
Zdravilo Glidipion je „generično zdravilo“.
Glidipion is a medicine that contains the active substance pioglitazone.
Glidipion je zdravilo, ki vsebuje zdravilno učinkovino pioglitazon.
Because Glidipion is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Ker je zdravilo Glidipion generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
What is the risk associated with Glidipion?
Kakšna tveganja so povezana z zdravilom Glidipion?
Glidipion should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease).
Zdravilo Glidipion se ne sme uporabljati pri bolnikih na dializi (tehniki čiščenja krvi, uporabljeni pri bolnikih z obolenjem ledvic).
EPAR summary for the public
Povzetek EPAR za javnost pioglitazon
Therefore, the CHMP's view was that, as for Actos, the benefits outweigh the identified risks.
Zato je menil, da njegove koristi, tako kot pri zdravilu Actos, odtehtajo znana tveganja.
Glidipion is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Zdravilo Glidipion se uporablja samostojno pri bolnikih, za katere metformin (drugo zdravilo proti sladkorni bolezni) ni primerno.
Why has Glidipion been approved?
Zakaj je bilo zdravilo Glidipion odobreno?
Glidipion can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy').
Lahko se uporablja tudi v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče doseči zadovoljivega nadzora, ali v kombinaciji s sulfonilsečnino (drugo vrsto zdravila proti sladkorni bolezni), če metformin ni primeren (zdravljenje z dvema zdraviloma).
Glidipion can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Lahko pa se uporablja tudi skupaj z insulinom pri bolnikih, pri katerih bolezen ni zadostno nadzorovana zgolj z insulinom in za katere metformin ni primeren.
Glidipion can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy').
Zdravilo Glidipion se lahko uporablja tudi skupaj z metforminom in sulfonilsečnino hkrati pri bolnikih, pri katerih nadzor ni zadosten kljub dvojnemu peroralnemu zdravljenju (zdravljenje s tremi zdravili).
What is Glidipion used for?
Za kaj se zdravilo Glidipion uporablja?
How does Glidipion work?
Kako zdravilo Glidipion deluje?
How has Glidipion been studied?
Kako je bilo zdravilo Glidipion raziskano?
What is Glidipion?
Kaj je zdravilo Glidipion?
How is Glidipion used?
Kako se zdravilo Glidipion uporablja?
Severe humoral or cellular (primary or acquired) immunodeficiency, e.g. severe combined immunodeficiency, agammaglobulinemia and AIDS or symptomatic HIV infection or an age-specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+ <25%; children between 12-35 months: CD4+ < 20%; children between 36-59 months: CD4+ < 15% (see section 4.4).
Huda humoralna ali celična (primarna ali pridobljena) imunska pomanjkljivost, npr. huda kombinirana imunska pomanjkljivost, agamaglobulinemija in AIDS ali simptomatska okužba s HIV ali za starost specifični odstotek CD4+ T-limfocitov pri otrocih mlajših od 12 mesecev: CD4+ < 25 %; pri otrocih med 12 in 35 mesecev: CD4+ < 20 %; pri otrocih med 36 in 59 mesecev: CD4+ < 15 % (glejte poglavje 4.4).
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before the vaccination is given.
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte s svojim zdravnikom ali s farmacevtom, preden boste prejeli to cepivo.
Whether you or your child receives the vaccine will depend upon the level of your immune defenses.
Ali boste vi ali vaš otrok prejeli cepivo, je odvisno od stopnje vašega imunskega odziva.
You or your child should be closely monitored as the responses to the vaccines may not be sufficient to ensure a protection against the illness (see section 2 “Do not use [PRODUCT NAME]”)
Vas ali vašega otroka je treba pozorno spremljati, ker odziv na cepljenje morda ne bo zadosten, da bi bila zagotovljena zaščita pred boleznijo (glejte poglavje 2 "Cepiva [IME CEPIVA] ne smete prejeti")
- if you or your child has any illness (such as Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)) or takes any medicine that weakens the immune system.
- če imate vi ali vaš otrok kakršnokoli bolezen (kot je virus humane imunske pomanjkljivosti (HIV) ali pridobljen sindrom imunske pomanjkljivosti (AIDS)) ali jemljete kakršnakoli zdravila, ki oslabijo imunski sistem.
The wording below should be inserted:
Vstaviti se mora spodnje besedilo:
During this time you should use an effective method of birth control to avoid pregnancy.
V tem času morate uporabljati zanesljivo metodo kontracepcije, da preprečite nosečnost.
Even if a theoretical risk cannot be excluded yet, no cases of congenital rubella syndrome have been reported in more than 3500 susceptible women who were unknowingly in early stages of pregnancy when vaccinated with rubella containing vaccines.
Čeprav teoretičnega tveganja še ne moremo izključiti, o nobenem primeru prirojenega sindroma rdečk niso poročali pri več kot 3500 dovzetnih ženskah, ki so bile v času cepljenja s cepivi, ki vsebujejo virus rdečk, nevede v zgodnjih fazah nosečnosti.
Warnings and precautions The text of this section should be read as follows:
Opozorila in previdnostni ukrepi Besedilo v tem razdelku se mora glasiti:
Talk to your doctor or pharmacist before you or your child receives [PRODUCT NAME]: - if you or your child has weakened immune system (e.g. such as HIV infection).
Posvetujte se s svojim zdravnikom, preden vi ali vaš otrok prejmete cepivo [IME CEPIVA]: - če imate vi ali vaš otrok oslabljen imunski sistem (kot je npr. okužba z virusom HIV).
Vaccination may be considered in patients with selected immune deficiencies where the benefits outweigh the risks (e.g. asymptomatic HIV subjects, IgG subclass deficiencies, congenital neutropenia, chronic granulomatous disease, and complement deficiency diseases).
Cepljenje lahko pride v poštev pri bolnikih z določenimi imunskimi pomanjkljivostmi, kadar koristi odtehtajo tveganja (npr. bolniki z asimptomatsko okužbo s HIV, pomanjkljivost podrazreda IgG, prirojeno nevtropenijo, kronično granulomatozno boleznijo in boleznijo z okvaro komplementa).
Section 4.4 Special warnings and precautions for use The wording on pregnancy and breastfeeding should be deleted.
Poglavje 4.4 Posebna opozorila in previdnostni ukrepi Besedilo glede nosečnosti in dojenja se mora izbrisati.
Also, it is important that you do not become pregnant within one month after having the vaccine.
Pomembno je tudi, da ne zanosite v roku enega meseca po cepljenju.
Section 4.6 Fertility, pregnancy and lactation The wording regarding pregnancy should read as follows:
Poglavje 4.6 Plodnost, nosečnost in dojenje Besedilo glede nosečnosti se mora glasiti:
What you need to know before you use [PRODUCT NAME] Do not use [PRODUCT NAME]
Kaj morate vedeti, preden boste prejeli cepivo [IME CEPIVA] Cepiva [IME CEPIVA] ne smete prejeti
The wording regarding pregnancy should read as follows: “[PRODUCT NAME] should not be administrated to pregnant women.
Besedilo glede nosečnosti se mora glasiti: “Nosečnic se ne sme cepiti s cepivom [IME CEPIVA].
Pregnant women should not be vaccinated with [PRODUCT NAME].
Nosečnic se ne sme cepiti s cepivom [IME CEPIVA].
Section 4.3 Contraindications The wording regarding pregnancy and immunocompromised patients should read as follows:
Poglavje 4.3 Kontraindikacije Besedilo glede nosečnosti in imunsko oslabelih bolnikov se mora glasiti:
Furthermore, pregnancy should be avoided for 1 month following vaccination (see section
Poleg tega ženska 1 mesec po cepljenju ne sme zanositi (glejte poglavje 4.6).
The wording regarding pregnancy and immunocompromised patients should read as follows:
Besedilo glede nosečnosti in imunsko oslabelih bolnikov se mora glasiti:
In case of inadvertent vaccination of pregnant women with [PRODUCT NAME], this should not be a reason for termination of pregnancy.
V primeru nenamernega cepljenja nosečnice s cepivom [IME CEPIVA] to ne sme biti razlog za prekinitev nosečnosti.
Pregnancy should be avoided for 1 month following vaccination.
Ženska ne sme zanositi 1 mesec po cepljenju.
These patients should be monitored carefully for signs of parotitis.
Te bolnike je treba pozorno spremljati glede znakov parotitisa.
These patients should be monitored carefully for signs of measles, parotitis, rubella and varicella.
Te bolnike je treba pozorno spremljati glede znakov ošpic, parotitisa, rdečk in noric.
These patients should be monitored carefully for signs of measles, parotitis and rubella.
Te bolnike je treba pozorno spremljati glede znakov ošpic, parotitisa in rdečk.
These patients should be monitored carefully for signs of measles.
Te bolnike je treba pozorno spremljati glede znakov ošpic.
In addition, pregnancy should be avoided for 1 month following vaccination.
Poleg tega 1 mesec po cepljenju ne smete zanositi.
Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent subjects, therefore some of these patients may acquire measles in case of contact, despite appropriate vaccine administration.
Pri bolnikih z oslabelo imunostjo, ki nimajo kontraindikacij za cepljenje s tem cepivom (glejte poglavje 4.3), odziv morda ne bo tako dober kot pri imunskokompetentnih osebah.
However, fetal damage has not been documented when mumps vaccines have been given to pregnant women.
Vendar pri uporabi cepiva proti mumpsu pri nosečnicah, niso zabeležili poškodb ploda.
Therefore, inadvertent vaccination of unknowingly pregnant women with measles, mumps and rubella containing vaccines should not be a reason for termination of pregnancy.
Zato nenamerno cepljenje nosečnice s cepivi, ki vsebujejo viruse ošpic, mumpsa in rdečk, ne sme biti razlog za prekinitev nosečnosti.
However, fetal damage has not been documented when measles, mumps, rubella or varicella vaccines have been given to pregnant women.
Vendar pri uporabi cepiva proti ošpicam, mumpsu, rdečkam ali noricam pri nosečnicah, niso zabeležili poškodb ploda.
Amendments to be included in the relevant sections of the package leaflet for multivalent measles, mumps and rubella containing vaccines 2.
Popravki, ki morajo biti vključeni v ustrezna poglavja navodila za uporabo za večvalentna cepiva, ki vsebujejo ošpice, mumps in rdečke 2.
Amendments to be included in the relevant sections of the package leaflet for monovalent mumps containing vaccines
Popravki, ki morajo biti vključeni v ustrezna poglavja navodila za uporabo za enovalentna cepiva, ki vsebujejo mumps
Amendments to be included in the relevant sections of the summary of product characteristics for multivalent measles, mumps and rubella containing vaccines
Popravki, ki morajo biti vključeni v ustrezna poglavja povzetka glavnih značilnosti zdravila za večvalentna cepiva, ki vsebujejo ošpice, mumps in rdečke
Amendments to be included in the relevant sections of the summary of product characteristics for monovalent mumps containing vaccines
Popravki, ki morajo biti vključeni v ustrezna poglavja povzetka glavnih značilnosti zdravila za enovalentna cepiva, ki vsebujejo mumps
However, fetal damage has not been documented when measles, mumps or rubella vaccines have been given to pregnant women.
Vendar pri uporabi cepiva proti ošpicam, mumpsu ali rdečkam pri nosečnicah, niso zabeležili poškodb ploda.